JAM1 Stock Overview
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tetra Bio-Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.013 |
| 52 Week High | CA$0.065 |
| 52 Week Low | CA$0.0046 |
| Beta | 2.26 |
| 1 Month Change | 0% |
| 3 Month Change | -0.79% |
| 1 Year Change | -59.28% |
| 3 Year Change | -92.13% |
| 5 Year Change | -97.16% |
| Change since IPO | -72.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| JAM1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -1.7% |
| 1Y | -59.3% | -32.1% | -0.2% |
Return vs Industry: JAM1 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: JAM1 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| JAM1 volatility | |
|---|---|
| JAM1 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: JAM1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine JAM1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 33 | Guy Chamberland | www.tetrabiopharma.com |
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma.
Tetra Bio-Pharma Inc. Fundamentals Summary
| JAM1 fundamental statistics | |
|---|---|
| Market cap | €8.97m |
| Earnings (TTM) | -€27.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs JAM1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAM1 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$39.02m |
| Earnings | -CA$39.02m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -28.1% |
How did JAM1 perform over the long term?
See historical performance and comparison